What signal is this?
On 10 November the MFDS issued a press reference note titled "Policy briefing held for cosmetic human clinical testing institutions". Trade coverage reports that the briefing takes place on 19 November at the Royal Hotel Seoul in Jung-gu, Seoul, and that the audience is cosmetic human clinical testing institutions. Those wishing to attend register in advance through the website of the Korea Association of Human Study Research Centers.
The agenda tells you what kind of room this is. It covers recent amendments to the labelling and advertising rules together with examples of violations, measures to secure the reliability of human study data for functional cosmetics, an introduction to ISO sunscreen test methods, pre-publication advisory and monitoring work for advertising, and the association's own monitoring activity. Rules, data reliability, test methods and post-launch monitoring have been gathered into one session.
The background given is market growth. According to the reporting, as the cosmetics market has expanded, advertising that draws on human studies has increased, and with it the importance of securing reliable evidence behind those claims. The MFDS says the intent is to help testing institutions run studies that meet labelling and advertising substantiation requirements.
The way a brand should read this is simple. The audience is not us, but the requirements discussed in that room apply to the people who build the evidence under our advertising lines. If testing institutions design protocols against substantiation requirements, then finishing a product first and later hunting for a usable sentence becomes slower and more expensive. Claim and study have to be settled at the same moment.
Four limits are worth stating. First, what is public is a notice that the briefing will take place; the presentation materials themselves are not yet published. Second, reports differ on the venue and the registration deadline, so actual attendance should be confirmed against the MFDS and association notices. Third, although "recent amendments to labelling and advertising rules" appears on the agenda, which notice takes effect when cannot be established from this announcement alone. Fourth, the judgements below are our reading of a published agenda; they do not guarantee a regulator's assessment or the acceptability of any particular wording.
1. You cannot design a study until the sentence exists
Substantiation is work done on a sentence, not on a product. Until you know what you intend to assert, you cannot know what to test, on how many people, for how many weeks. The first box in a brief that must not be empty is therefore not the active ingredient but the sentence you want to use.
Different sentences carry different evidential weight. A line describing texture or sensory feel, a line stating that an ingredient is present, and a line putting a number on a change after use cannot sit on the same row. The further down that list you go, the heavier the required evidence, and the longer and costlier the study.
In practice it helps to narrow the candidates to three or four written-out sentences. Put one line beside each saying what would have to exist for that sentence to be usable, and it becomes obvious which sentence is the product's core and which is decoration you can drop. Usually the fastest way to cut cost is not to change the formula but to cut sentences.
Run the order backwards and you pay twice. Lock the printed packaging and the product page first, then go looking for evidence, and when the data fails to support the line, what has to change is not one sentence but the whole print run and the content around it.
Choosing the sentence is not marketing's job alone. What can be measured is decided by the formula, and what is measurable is known by the testing institution. One early meeting where all three sides look at the same table is cheaper than rewriting lines days before launch.
- Whether three or four candidate sentences are written at the front of the brief
- Whether each sentence carries a line naming the evidence it needs
- Whether decorative sentences have been separated from core ones
- Whether formulation, marketing and testing meet over the same table
2. The type of evidence reshapes the schedule
That the agenda places reliability of human study data alongside ISO sunscreen test methods shows there is more than one kind of evidence. Studies on people, instrument or plate based methods, and existing research literature differ in preparation time and in what they produce.
For a brand that difference shows up as the shape of the schedule. The choice of evidence determines how many samples must exist and by when, when results arrive, and how many days remain between those results and the print order. The same product can have different possible launch dates depending on which evidence it rests on.
Every study also demands a fixed sample. Work cannot start while the formula is still moving, and if the formula is touched after the study, that data belongs to a different product. The date the formula is frozen is in effect the date testing starts, and that date pushes the launch date.
So build the schedule backwards from launch. Write launch date, print order date, results date, study start date, formula freeze date and sample production date in one row, and it becomes visible what has to stop today. A brief missing that row usually slips once.
Cost moves the same way. Deciding to use more evidence is a decision to add test items, and test items add samples and weeks at the same time. That is why cutting sentences was the cheapest choice in the previous section.
- Whether the kind of evidence is decided sentence by sentence
- Whether the formula freeze date is written as the study start date
- Whether the brief contains a schedule counted backwards from launch
- Whether the effect of test item count on samples and weeks was calculated
3. Functional products carry a separate reliability question
It is worth noting that "measures to secure the reliability of human study data for functional cosmetics" appears as its own agenda item. It suggests that evidence behind general cosmetic advertising and data submitted for functional cosmetics, however similar the study looks, are treated at different levels of management.
The decision a brand has to make at the planning stage is therefore a single one: does this product go the functional route or the general cosmetic route. Settle that line and the kind of data needed, the design of the study, the length of the schedule and the range of wording available on the pack are all settled at once.
Leave the line blank and everything moves to "later". The common failure path is developing as a general cosmetic and then wanting functional wording at the marketing stage. By then the formula, the container and the printed matter are fixed and there is almost nothing left to reverse.
Choosing the testing institution becomes a planning variable too. If data reliability is being managed, where a study was run matters as much as what it found. Rather than picking on price alone, check the institution's experience with that specific test item and how it writes up its data.
One thing should be stated plainly. Whether a given product falls under the functional category, and what data it needs, differs by product and has no general answer. The planning-stage task is not to decide the answer but to schedule when, and to whom, that question gets put.
- Whether functional or general cosmetic is settled in one line
- Whether the effect of that choice on wording and schedule is written down
- Whether testing institutions were compared on experience, not only price
- Whether the question of product classification is scheduled with an owner
4. For sun care the test method is itself a specification
The presence of ISO sunscreen test methods on the agenda matters most to brands preparing sun care. For a sun protection product the declared factor is the advertising line, and how that figure was obtained is the evidence itself.
A sun care brief therefore gains a box no other category has: by which method will the factor be produced. That box affects not only schedule and cost but the direction of the formula, because the measurement method has to be settled before you can judge which UV filter combination at which percentages is worth pursuing.
Plan for export and another box appears. Markets do not necessarily recognise the same methods or the same declaration formats, so fixing the domestic declaration first and fitting overseas markets afterwards can mean running the same study twice. That is why the target market belongs in the brief before the formula is frozen.
What this briefing notice cannot tell you is how far any method is recognised. That a method is being introduced on an agenda and that it is accepted as the basis for a specific declaration are two different statements. Scope has to be confirmed against the text of the relevant notice and its effective date.
The order we would recommend is this. Write the target factor and the target markets, confirm with a testing institution which methods are available for that combination, and only then narrow the formulation range. Building the formula first and measuring afterwards leaves nowhere to retreat when the number does not come out as hoped.
- Whether target SPF and target markets are written before the formula freeze
- Whether the method for producing the factor was confirmed with a testing institution
- Whether domestic and overseas declarations sit in the same table
- Whether the method's recognised scope was checked against the notice and its effective date
5. The same evidence gets called back after launch
The agenda also includes pre-publication advisory and monitoring work for advertising, along with the association's own monitoring activity. Both the stage where evidence is produced and the stage after it has been used in advertising are handled in the same room.
For a brand that turns into a filing problem. Evidence is not finished when it is produced; it has to be connectable on demand, so that "the basis for this sentence is this document" can be shown immediately. The most common risk is a results file sitting in one person's folder with nothing written down about which sentence it supports.
Hence the one-page mapping table we recommend. On the left, the sentences actually in use; on the right, the document supporting each one, the testing institution, the study date and where the file is kept. If the product page, the pack and the ad creative are using different sentences, the table shows that too.
Renewals break this table most often. Changing a fragrance or adjusting viscosity is a change of sample, and the existing data may stop being data about the product you are currently selling. Add a box to your formula change-approval process asking whether this change affects existing evidence.
The more channels you add, the more the table earns its keep. When the domestic product page, the submission pack for an overseas retailer and social creative are made by different hands, sentences drift upward in their claims. A shared evidence table stops that drift at least once.
- Whether a one-page table maps sentences to supporting evidence
- Whether the storage location and owner of each document is on the table
- Whether change control asks about impact on existing evidence
- Whether product page, pack and ad creative start from the same table
The first question for the brief
Replace the line that reads "emphasise efficacy" with three lines. The first is the sentence: write out, in quotation marks, exactly what will be printed on the pack and the product page. Summarise it, or blur it into "improves X and so on", and that line is not yet a decision.
The second line is the evidence. Beside the sentence, write what kind of data will support it, at which testing institution, starting when and reporting when. Writing that line makes visible that the formula freeze has to move earlier, because a study only begins on a fixed sample.
The third line is custody. Write where the results will be kept once received, who manages them, and who revisits them when a renewal changes the formula. The most useful single line to add to the brief today is: where, right now, is the evidence for the sentence we are about to print.
Sources
- [보도참고자료] 화장품 인체적용시험기관 대상 정책설명회 개최 — 식품의약품안전처, 2026-11-10
- 화장품 인체적용시험기관 대상 정책설명회... 11월 19일 개최 — 코스인코리아닷컴
- 화장품 인체적용시험기관 대상 정책설명회 11월 19일 개최 — CNC News
For more context, see the product development guide and MOQ 1,000 guide.